FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma

KIT is a bona fide oncogene in a subset of melanoma and, ex vivo, KIT inhibitors are very efficient at killing KIT-mutant melanoma cell lines. However, KIT-mutant melanoma tumors tend to show a de novo resistance in most cases and a limited duration of response when response is achieved. We performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tétu, Pauline, Delyon, Julie, André, Jocelyne, Reger de Moura, Coralie, Sabbah, Malak, Ghanem, Ghanem E, Battistella, Maxime, Mourah, Samia, Lebbé, Céleste, Dumaz, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281633/
https://www.ncbi.nlm.nih.gov/pubmed/32344828
http://dx.doi.org/10.3390/cancers12051062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281633/
https://www.ncbi.nlm.nih.gov/pubmed/32344828
http://dx.doi.org/10.3390/cancers12051062

Ejemplares similares